PTSD & trauma recovery

What changes during this transition

Trauma-focused psychotherapy is the dominant intervention for PTSD, full stop. Cognitive Processing Therapy, Prolonged Exposure, and EMDR are the VA/DoD 2023 and APA 2017 guideline first-line treatments and outrank any peptide selection by an enormous margin. Medication first-line is the SSRI pair with formal FDA approval — sertraline and paroxetine — with venlafaxine as the off-label guideline-recommended SNRI. Adjuncts within standard care include prazosin for trauma nightmares (the Raskind 2018 primary endpoint was negative but community clinical use continues), topiramate, and second-generation antipsychotics where psychosis features are present. The peptides surfaced here are coordinated with a treating psychiatrist or trauma-focused psychologist — none of them belong in self-directed protocols, and the therapy program is the dominant intervention in every case. The MDMA-assisted-therapy conversation has reshaped what users ask about for severe and treatment-resistant PTSD over the past several years. The MAPS Phase 3 program (MAPP1 Mitchell 2021, MAPP2 Mitchell 2023 in Nature Medicine) reported approximately 67% of treated participants no longer meeting PTSD criteria at study end — a remission rate that legitimately changed the clinical conversation. The FDA rejected the Lykos NDA in August 2024 citing methodological concerns around unblinding, expectancy effects, and abuse-liability, and MDMA-assisted therapy remains not FDA-approved as of 2026. We surface that context here because users sometimes substitute peptide picks into the conceptual space that MDMA-assisted therapy occupied in the conversation — and the substitution isn't supported by the peptide evidence base. Ketamine and esketamine (Spravato is FDA-approved for treatment-resistant depression including with PTSD comorbidity) are separate conversations that belong with the treating psychiatrist. Oxytocin earns the strongest peptide spot here — it is the most-studied peptide in PTSD research, with the Amsterdam emergency-department early-intervention work (Frijling 2017, van Zuiden 2017, Nawijn 2017), the Koch 2016 established-PTSD pilot, the Flanagan 2018 PE-augmentation work, and the Donadon 2018 meta-analysis providing a real if mixed evidence base; the signal is cleanest as an augmenter to trauma-focused psychotherapy in clinician-supervised protocols, never as a self-administered intervention. Selank addresses the autonomic hyperarousal overlay of PTSD on the basis of its Russian-registered anxiolytic indication, with the load-bearing benzodiazepine-sparing taper context — psychiatrist-managed, never user-directed. Kisspeptin is emerging neuropsychiatric specialist territory drawing on the Comninos limbic-circuit imaging work; preliminary as a clinical PTSD signal but interesting enough to surface honestly when users ask. B12-methylcobalamin earns a place because confirmed B12 deficiency masquerading as PTSD-related cognitive symptoms or fatigue is a documented clinical scenario, especially in veteran populations where deficiency prevalence is elevated. What's not in the browse picks: BPC-157. It is heavily marketed in trauma-recovery community spaces on a gut-vagal-axis polyvagal-theory framing that runs well ahead of any human evidence — there is no published human PTSD, anxiety, depression, or trauma trial, and the rodent CNS work doesn't propagate to a human treatment claim. The substrate entry exists so /ask can answer honestly when users raise it, and the answer is honest about the absent evidence; the discovery surface should not elevate it as an option.